Clinical outcome trials evaluating primary cardiovascular disease prevention with aspirin in Type 2 diabetes may need to consider using a more frequent dosing schedule.
Clinical outcome trials evaluating primary cardiovasculardisease prevention with aspirin in Type 2 diabetes may need to consider using a more frequent dosing schedule.